Welcome to our dedicated page for Orthofix Med news (Ticker: OFIX), a resource for investors and traders seeking the latest updates and insights on Orthofix Med stock.
Orthofix Medical Inc. reports developments across its orthopedic and spine medical technology portfolio. The company provides spinal implants, therapeutic solutions, limb reconstruction systems, biologics and enabling technologies, including the 7D FLASH Navigation System, for complex musculoskeletal conditions.
Recurring OFIX news includes quarterly results, guidance, product launches and commercial execution in Spine and Orthopedics. Company updates also cover pediatric limb reconstruction offerings such as FITBONE, planning software such as OrthoNext, the TRUELOK Elevate system, spine leadership realignment, distributor transitions, biologics activity and the discontinued M6 artificial disc product lines.
Orthofix Medical Inc. (NASDAQ:OFIX) announced participation in the Sidoti Virtual Investor Conference on September 23, 2021, at 2:30 p.m. ET. President and CEO Jon Serbousek and CFO Doug Rice will engage in a fireside chat, with one-on-one meetings before and after the session. Interested parties can access the live webcast on the company’s website. Orthofix focuses on innovative medical solutions in spine and orthopedics, distributing products in over 60 countries. For more information, visit www.orthofix.com.
Orthofix Medical Inc. (NASDAQ:OFIX) announces the first U.S. pediatric patient implanted with the Fitbone intramedullary lengthening system. This FDA-cleared solution is designed for limb lengthening of the femur and tibia, available in sizes 9mm, 11mm, and 13mm. The Fitbone system is now compatible with the OrthoNext digital platform, enhancing preoperative planning. The system has been successfully used in over 3,500 cases globally, reflecting Orthofix's commitment to improving patient outcomes in orthopedic care.
Orthofix Medical Inc. (NASDAQ:OFIX) reported Q2 2021 financial results, with net sales of $121 million and EPS of $0.12. Adjusted EPS rose to $0.32, reflecting improved performance over pre-COVID levels. Key growth drivers include the M6-C cervical disc and FITBONE lengthening system. Gross profit increased to $94 million, with a gross margin of 77.4%. However, cash flow from operations fell to $0.3 million. The 2021 outlook anticipates net sales between $468 million and $474 million, representing a 15.1% to 16.6% increase.
Orthofix Medical Inc (NASDAQ:OFIX) announced the first patient implant in a pivotal FDA clinical study evaluating the M6-C™ artificial cervical disc for two-level cervical radiculopathy. This study will compare the disc's safety and effectiveness against anterior cervical discectomy and fusion (ACDF). A total of 263 patients will be enrolled, aiming for a primary endpoint of overall success at 24 months. The M6-C disc has been implanted over 55,000 times globally, reinforcing its position as a promising alternative to cervical fusion.
Orthofix Medical Inc. (NASDAQ:OFIX) has announced it will release its second quarter 2021 financial results on Friday, August 6, 2021, before the market opens. The company’s President, Jon Serbousek, and CFO, Doug Rice, will conduct a conference call at 8:30 a.m. ET to discuss the results. Interested parties can access the call by dialing specific numbers or through a webcast available on the company's investor relations website.
Orthofix Medical Inc. (NASDAQ:OFIX) has launched the fiberFUSE™ Strip, a new bone-graft solution for spinal procedures. This innovative product is composed entirely of natural bone and is designed for optimized application in cervical and lumbar surgeries. The fiberFUSE Strip enables cellular ingrowth and new bone formation due to its unique composition. The technology was developed to provide convenience and effectiveness for spine surgeons and their patients. MTF Biologics is the exclusive processor of this product, ensuring high-quality standards through validated aseptic processing.
Orthofix Medical Inc. (NASDAQ:OFIX) announced significant findings from a retrospective study published in The International Journal of Spine Surgery, highlighting a 92.7% fusion rate for patients undergoing three- and four-level lumbar arthrodesis surgery with the SpinalStim device. This data, gathered from 55 patients, reinforces the effectiveness of Pulsed Electromagnetic Field Stimulation (PEMF) therapy even among high-risk patients. The device is FDA-approved for lumbar spinal fusion procedures and is supported by the STIM onTrack mobile app, enhancing patient engagement in recovery.
Orthofix Medical Inc (NASDAQ: OFIX) has launched the FORZA Ti PLIF Spacer System in the U.S., designed for enhancing Posterior Lumbar Interbody Fusion (PLIF) procedures. The device is 3D-printed with optimized porosity and features to support bone ingrowth, critical for surgical success. Key features include a large graft window, titanium endplates with 400 micron pores, and a functional gradient porous structure. The FORZA Ti system is part of Orthofix's growing portfolio of innovative 3D-printed titanium products aimed at improving surgical outcomes.
Orthofix Medical, a global medical device company focused on spine and orthopedics, announced that CEO Jon Serbousek and CFO Doug Rice will participate in a fireside chat at the JMP Securities Life Sciences Conference on June 16, 2021, at 11:00 a.m. ET. The virtual event will include one-on-one meetings and a live audio webcast available on the Company’s website for interested stakeholders.
Orthofix aims to deliver innovative solutions to enhance patient mobility and distributes its products in over 60 countries.
Orthofix Medical Inc. (NASDAQ:OFIX) will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:30 p.m. ET. CEO Jon Serbousek and CFO Doug Rice will lead the discussion. The chat will be followed by one-on-one meetings. A live audio webcast can be accessed on the Company's website.
Orthofix specializes in innovative medical devices and biologics for spine and orthopedics, aiming to enhance patient mobility. Its products are distributed in over 70 countries from its headquarters in Lewisville, Texas.